Fatima Gulzar

5 days ago | insidermonkey.com | Fatima Gulzar

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks.

5 days ago | insidermonkey.com | Fatima Gulzar

Twist Bioscience Corporation (NASDAQ:TWST) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The firm has expanded its relationship with Element Biosciences to produce end-to-end Next Generation Sequencing (NGS) solutions. Twist Bioscience Corporation (NASDAQ:TWST)’s library prep and target enrichment workflows are now integrated with Element’s AVITI™ devices and Trinity™ flowcells.

5 days ago | insidermonkey.com | Fatima Gulzar

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc.

5 days ago | insidermonkey.com | Fatima Gulzar

Exact Sciences Corporation (NASDAQ:EXAS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has released fresh data from the Beta-CORRECT study that validates the clinical efficacy of its tumor-informed Oncodetect™ test for recurrence monitoring in stage II-IV colorectal cancer. The findings, presented at ASCO 2025, revealed that patients with ctDNA-positive results after therapy and during surveillance had a 24- and 37-fold greater risk of recurrence, respectively.

5 days ago | insidermonkey.com | Fatima Gulzar

10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms. As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments.